H.Res. 1125 · 116th Congress
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies…
Full title
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
EngelSponsor22 cosponsors · 22 D
D
Bera
NB
D
Barragán
SC
D
Cohen
GC
D
Cisneros
AE
D
Espaillat
JH
D
Hayes
SJ
D
Jackson Lee
EJ
D
Johnson
BL
D
Lee
JM
D
McGovern
GM
D
Meeks
JN
D
Nadler
EN
D
Norton
DP
D
Price
DP
D
Payne
AS
D
Sires
TS
D
Sewell
MS
D
San Nicolas
DT
D
Trone
JC
D
Castro
JC
D
Chu
EL
D
Luria19 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
What it does: CRS summary · Introduced in House · Sep 18, 2020
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
Latest action (Sep 18, 2020): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Sep 18, 2020
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.